ArticleNutrients2025
Gut-Protective and Multifunctional Exopolysaccharide from
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Macleaya Cordata Extract on LPS-Induced Intestinal Inflammation and Diarrhea via Modulation of Gut Microbiota.Animals : an open access journal from MDPI · 2026Article
- Therapeutic Potential and Functional Mechanisms of Probiotics as Prospective anti-inflammatory Agents.Probiotics and antimicrobial proteins · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEnteropathogenic
resultsEPS-T1, with a molecular weight of 81.21 ± 1.28 kDa, was mainly composed of glucose, galactose, rhamnose, and mannose, and exhibited a porous, sheet structure with relatively high thermal stability. In vitro, EPS-T1 (200 μg/mL) significantly inhibited EPEC growth and biofilm formation, reduced bacterial adhesion to intestinal epithelial cells, and exhibited broad-spectrum free radical scavenging activity. In vivo, EPS-T1 treatment alleviated EPEC-induced weight loss and intestinal tissue damage, reduced the intestinal EPEC load, downregulated pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), upregulated the anti-inflammatory cytokine IL-10, and improved serum antioxidant indices (T-AOC, SOD, and GSH-PX) while decreasing MDA levels.
conclusionsThese results demonstrate that EPS-T1 derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.